Observational Study on Prevalence of Adverse Effects of COVID Vaccination among General Population in South India
Abstract
Introduction: COVID-19 is a viral disease due to the Severe Acute Respiratory Syndrome Coronavirus 2. The patients show flu-like symptoms with a dry cough, sore throat, high fever, and breathing problems. This was conducted to assess the adverse effects after taking Covid 19 vaccines in general population of Kerala state.
Methodology: About 353 participants were enrolled in the study according to inclusion and exclusion criteria for a period of November 2021 to April 2022. Data collection was done with structured questionnaire in google form. The data were analysed and reported using tables, pie diagram, bar diagrams and different charts forms.
Results: Majority of patients enrolled in the study were vaccinated with 2 dosed of Covid vaccines. From 351 participants vaccinated with Covid 19 vaccine 249 experienced an AEFI. The most reported AEFI was fever, body pain and injection site reactions. From the results it was found that females had experienced more AEFI than males. Most of the participants from our study were vaccinated with Covishield and all participants taken Sputnik vaccine had experienced some adverse effects.
Conclusion: The present study reveal that majority of people vaccinated by Covid 19 vaccines had experienced any kind of AEFIs. Majority of patients enrolled in the study were vaccinated with 2 dosed of Covid vaccines. The most reported AEFI was fever, body pain and injection site reactions. From the results it was found that females had experienced more AEFI than males.
Keywords: Adverse effects, Covid 19, Covishield, Covaxin, Immunization, Vaccination
Downloads
References
2. Bhalwar R, Vaidya R, editors. Text book of public health and community medicine. Department of Community Medicine, Armed Forces Medical College; 2009.
3. Akarsu B, Canbay Özdemir D, Ayhan Baser D, Aksoy H, Fidancı İ, Cankurtaran M. While studies on COVID‐19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID‐19 vaccine. Int J Clin Pract. 2021; 75(4):e13891. https://doi.org/10.1111/ijcp.13891
4. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021; 111:219-226. https://doi.org/10.1016/j.ijid.2021.08.013
5. Selvaggio G, Leonardelli L, Lofano G, Fresnay S, Parolo S, Medini D, Siena E, Marchetti L. A quantitative systems pharmacology approach to support mRNA vaccine development and optimization. CPT: Pharmacometrics & Systems Pharmacology. 2021; 10(12):1448. https://doi.org/10.1002/psp4.12721
6. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021:1663-1669.
7. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology E-book. Elsevier Health Sciences; 2014 Aug 22.
8. Bonhoeffer J, Heininger U. Adverse events following immunization: perception and evidence. Curr Opin Infect Dis. 2007; 20(3):237-246. https://doi.org/10.1097/QCO.0b013e32811ebfb0
9. Bates DW, Boyle DL, Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Int Med 1995; 10(4):199-205. https://doi.org/10.1007/BF02600255
10. Nishat J, Fahad IR, Poushali S, Sadia AE, Rotnuzzaman AS, Rapty S et al. Side Effects Following Administration of the First Dose of Oxford-AstraZeneca's Covishield Vaccine in Bangladesh: A Cross-Sectional Study. Infect Dis Rep. 2021; 13(4):888-901. https://doi.org/10.3390/idr13040080
11. Rajpurohit P, Suva M, Rajpurohit H, Singh Y, Boda P. A Retrospective observational survey of adverse events following immunization comparing tolerability of Covishield and Covaxin vaccines in the real world. J Pharmacovig Drug Res. 2021; 2(3):20-25. https://doi.org/10.53411/jpadr.2021.2.3.5
12. Tobaiqy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines. 2021; 9(4):393. https://doi.org/10.3390/vaccines9040393
13. Alfaleh A, Alkattan A, Radwan N, Elzohri M, Alzaher A, Ibrahim M, Alsalameen E, Alsultan A, Alhabib D, Alshelwah A, Mahmoud N. Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. Drugs & Therapy Perspectives. 2022; 38:84-92. https://doi.org/10.1007/s40267-022-00893-y
14. Jeon M, Kim J, Oh CE, Lee JY. Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea. Vaccines. 2021; 9(10):1096. https://doi.org/10.3390/vaccines9101096
15. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Müller B, Noveanu M. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA. 2019; 322(23):2292-302. https://doi.org/10.1001/jama.2019.18598
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.